Schlagwörter
Heart failure
Paradox
Mistaken identity
Abstract
Background: Obesity paradox is a clinical situation
where obesity confers benefit. This is anachronistic
considering that obesity increases the risk of
cardiovascular diseases like heart failure (HF). This
raises the question of whether obese patients with
clinically diagnosed HF were actually in HF.
Methods: This was a secondary analysis of data
generated in a larger study on Prevalence of
Dysnatraemia in HF patients admitted on our service.
History, physical and 2D echocardiographic
examinations were done for the study patients. Blood
was taken for point of care NT- pro BNP assay.
Echo and BNP data were divided along weight group
lines and compared
Results: There were 120 patients; 69 males and 51
females aged between 18 to 92 years with a mean
of 51.9 + 16.67 (SD) years. The NT-pro BNP levels
ranged from 301.0 to 950.0 pg/ml with a mean of
509.7 +_ 161.9 (SD) pg/ml. Applying the appropriate
age specific cut off values, 25/120 (20.8%) were
accurately identified as HF; while 95/120 (79.2%)
were misclassified. Of the 120, 13 were obese, 29
overweight and 78 normal. 11/13 of the obese
(84.6%) were misclassified. 22/29 overweight
(75.9%) were misclassified and 62/78 with normal
weight (79.5%) were misclassified. The proportion
misclassified was high across board but highest for
the obese category. Mean ejection fraction (EF) rose
significantly (p = 0.037) with BMI; more for males
(p=0.019) than females (p = 0.54). Using EF > 50%
to define heart failure with preserved ejection fraction
(HFpEF) BMI was higher in HFpEF compared with
HFrEF to a statistically significant level, p = 0 001
again more in males than females.
Conclusion: Using BNP as a marker of HF in the
obese gives inconsistent results; and should be
reserved for prognostication and follow- up. Most
obese people are likely to present with clinical
features of HF without actually being in HF.
Literaturhinweise
Lavie CJ, Alpert MA, Arene R, Mehra MR,
Milani RN, Ventura HO. Impact of obesity and
obesity paradox on prevalence and prognosis of
heart failure. JACC Heart Failure. 2013; 1: 93 –
Ariza-Sole A, Salazar-Mendiguchia J, Lorente
V et al. A Body mass index and acute coronary
syndromes. Paradox or confusion. Eur. Ht J.
Acute Cardiovascular Care. 2015; 4(2): 158 –
Kenchaiah S, Evans JC, Levy D et al. Obesity
and the risk of heart failure. NEJM. 2002; 347:
– 313
Lavie CJ, Milani RV, Ventura HO. Obesity and
cardiovascular disease: risk factor paradox and
impact of weight loss. J Am Coll Cardiol. 2009;
: 1925 – 1932.
Obesity paradox in Heart Failure
Ankar SD, Ponikowski PP, Clark AL et al.
Cytokines and neurohormones relating to body
composition alterations in the wasting syndrome
of chronic heart failure. Eur Ht J. 1999; 20: 683
– 693.
Okoshi MP, Romeiro FG, Martinez PF, Oliveria
Jr. SA, Polegasto RF, Okoshi K. Cardiac
cachexia and muscle wasting. Definition
pathophysiology and clinical consequences.
Research Reports in Clinical Cardiology. 2014;
: 319 – 326.
Oyedeji AT, Balogun MO, Akintomide AO,
Sunmonu TA, Adebayo RA, Ajayi OE. The
“Obesity paradox” in Nigerians with heart failure.
Ann Afr Med. 2012; 11: 212 – 216.
Schiller NB, Shah PM, Crawford M et al.
Recommendations for quantitation of the left
ventricle by two dimensional echocardiography.
American Society of Echocardiography
Committee on Standards, sub-committee on
quantitation of two dimensional
echocardiography. J. Am. Soc. Echo. 1989; 2(5):
– 367.
Maisel A, Mueller C, Adams K Jr et al. State of
the art using natriuretic peptide levels in clinical
practice. Eur J. Ht Fail. 2008; 10(9): 824 – 839.
Hobbs RE. Using Brain Natriuretic Peptides to
Diagnose, Manage and Treat Heart Failure.
Cleveland Clinic J. Med. 2003; 70(4): 333 – 336.
Kalsmith BM. Role of Brain Natriuretic Peptides
in Heart Failure Management. Circ. Heart Fail.
; 2: 379. https://doi.org/10.1161/
CIRCHEARTFAILURE.108.816264
Doust J, Lehman R, Cidaszion P. The Role of
BNP testing in Heart Failure. Am. Fam. Phys.
; 27(11): 1893 - 1900
Latini R, Masson S, Anand I et al. (for the
Valsartan Heart Failure Trial Investigators).
Effects of Valsartan on circulating brain
natriuretic peptide and norepinephrine in
symptomatic chronic heart failure: the Valsartan
Heart Failure Trial (Val-HeFT). Circulation. 2002;
: 2454 – 2458.
Yoshizawa A, Yoshikawa T, Nakamura I et al.
Brain natriuretic peptide response in
heterogenous during beta blocker therapy for
congestive heart failure. J. Card Fail. 2004; 10:
– 315.
Hussaini A, Lutfi IA, Afridi AI. Diagnostic cut
off levels of plasma brain natriuretic peptides to
distinguish left ventricular function in emergency
setting. J. Coll Physicians Surg Pak. 2014; 24(5):
– 307. Doi:04.2014/JCPSP.0304307.
Sharma V, Stewart RA, Lee M et al. Plasma
brain natriuretic peptide concentrations in patients
with valvular heart disease. Open Heart. 2016;
: e000184. Doi: 10.1136/0penhrt-2014-000184.
Arzilli C, Aimo A, Vergaro G et al. N-terminal
fraction of pro-B type natriuretic peptide versus
clinical risk scores for prognostic stratification in
chronic systolic heart failure. Eur. J. Prev
Cardiol. 2018; 25(8): 889 – 895.
Donst J, Lehman R, Glaszi M. The role of BNP
testing in heart failure. Am Fam Physician. 2006;
: 1893 – 1898.
Anand IS, Fisher LD, Chiang YT et al. (for the
Val-HeFT Investigators). Changes in brain
natriuretic peptide and norepinephrine over time
and mortality and morbidity in the Valsartan Heart
Failure Trial (Val-HeFT). Circulation. 2003; 107:
– 1283.
Riaz H, Khan MS, Siddiqi TJ et al. Association
beween obesity and cardiovascular outcomes.
A systematic review and meta-analysis of
mendelian randomization studies. JAMA
Network Open 2018; 1(7):e183788.doi:10.1001/
jamanetworkopen.2018.3788.
McCord J, Mundy BJ, Hudson MP et al.
Relationship between obesity and B-type
Natriuretic peptide levels. Arch. Int. Med. 2004;
: 2247 – 2252.
Caruana L, Petric MC, Davie AP, McMurray
JJV. Do patients with suspected heart failure and
preserved left ventricular function suffer from
“diastolic heart failure” or from misdiagnosis? A
prospective descriptive study. BMJ. 2000; 321:
– 218.
Bischoff SC, Boirie Y, Cederholm T. Towards a
multidisciplinary approach to understand and
manage obesity and related diseases. Clinical
Nutr. 2017; 36: 917 – 935.